However, in small clinical trials regarding cancer, treatment with anti-IL6 or anti-IL6R has shown no clinical effect in patients multiple myeloma [127, 128], metastatic renal cell cancer [129] and castration-resistant prostate cancer [47]. Here, IL6 is linked to cancer.